These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1621415)

  • 41. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
    Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease.
    Lee YN; Suk Hwang H; Kim MC; Lee YT; Cho MK; Kwon YM; Seok Lee J; Plemper RK; Kang SM
    Virology; 2015 Feb; 476():217-225. PubMed ID: 25553517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses.
    Russell CJ; Hurwitz JL
    Expert Rev Vaccines; 2016; 15(2):189-200. PubMed ID: 26648515
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical experience with respiratory syncytial virus vaccines.
    Piedra PA
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S94-9. PubMed ID: 12671459
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.
    Cayatte C; Snell Bennett A; Rajani GM; Hostetler L; Maynard SK; Lazzaro M; McTamney P; Ren K; O'Day T; McCarthy MP; Schneider-Ohrum K
    PLoS One; 2017; 12(11):e0188708. PubMed ID: 29182682
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recent advances in the development of subunit-based RSV vaccines.
    Jaberolansar N; Toth I; Young PR; Skwarczynski M
    Expert Rev Vaccines; 2016; 15(1):53-68. PubMed ID: 26506139
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunosuppression of the antibody response to respiratory syncytial virus (RSV) by pre-existing serum antibodies: partial prevention by topical infection of the respiratory tract with vaccinia virus-RSV recombinants.
    Murphy BR; Collins PL; Lawrence L; Zubak J; Chanock RM; Prince GA
    J Gen Virol; 1989 Aug; 70 ( Pt 8)():2185-90. PubMed ID: 2671259
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Respiratory syncytial virus and parainfluenza virus.
    Hall CB
    N Engl J Med; 2001 Jun; 344(25):1917-28. PubMed ID: 11419430
    [No Abstract]   [Full Text] [Related]  

  • 51. Current progress on development of respiratory syncytial virus vaccine.
    Chang J
    BMB Rep; 2011 Apr; 44(4):232-7. PubMed ID: 21524347
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children.
    Iwane MK; Edwards KM; Szilagyi PG; Walker FJ; Griffin MR; Weinberg GA; Coulen C; Poehling KA; Shone LP; Balter S; Hall CB; Erdman DD; Wooten K; Schwartz B;
    Pediatrics; 2004 Jun; 113(6):1758-64. PubMed ID: 15173503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fusion of DsbA to the N-terminus of CTL chimeric epitope, F/M2:81-95, of respiratory syncytial virus prolongs protein- and virus-specific CTL responses in Balb/c mice.
    Fan CF; Zeng RH; Sun CY; Mei XG; Wang YF; Liu Y
    Vaccine; 2005 Apr; 23(22):2869-75. PubMed ID: 15780735
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines.
    Crowe JE; Firestone CY; Murphy BR
    J Immunol; 2001 Oct; 167(7):3910-8. PubMed ID: 11564809
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting.
    Murphy BR; Collins PL
    Bull World Health Organ; 1997; 75(4):307-13. PubMed ID: 9342889
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Humoral immunity to respiratory syncytial virus infection in the elderly.
    Falsey AR; Walsh EE
    J Med Virol; 1992 Jan; 36(1):39-43. PubMed ID: 1573388
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protection of cotton rats against human respiratory syncytial virus by vaccination with a novel chimeric FG glycoprotein.
    Brideau RJ; Walters RR; Stier MA; Wathen MW
    J Gen Virol; 1989 Oct; 70 ( Pt 10)():2637-44. PubMed ID: 2677234
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in mice.
    Johnson JE; McNeil LK; Megati S; Witko SE; Roopchand VS; Obregon JH; Illenberger DM; Kotash CS; Nowak RM; Braunstein E; Yurgelonis I; Jansen KU; Kalyan NK; Sidhu MK
    Immunol Lett; 2013 Feb; 150(1-2):134-44. PubMed ID: 23261719
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enhanced humoral and CD8+ T cell immunity in mice vaccinated by DNA vaccine against human respiratory syncytial virus through targeting the encoded F protein to dendritic cells.
    Hua Y; Jiao YY; Ma Y; Peng XL; Fu YH; Zhang XJ; Zheng YB; Zheng YP; Hong T; He JS
    Int Immunopharmacol; 2017 May; 46():62-69. PubMed ID: 28259002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.